Latest news

Thumbnail image for Prescription charge in England to rise

Prescription charge in England to rise

The government is aiming to increase the prescription charge by 20 pence per item to help it deliver its promise of streaming £10 billion into frontline NHS services by 2020/21, but campaigners say the system is "unfair".

27th February 2018

Thumbnail image for EU clears rare musculoskeletal disorder drug

EU clears rare musculoskeletal disorder drug

Doctors can now treat children living in the EU with the rare, chronic progressive musculoskeletal disorder X–Linked Hypophosphataemia with Kyowa Kirin/Ultragenyx’ Crysvita following its conditional approval in the region.

26th February 2018

Thumbnail image for AZ/MSD’s Lynparza wins new CHMP nod

AZ/MSD’s Lynparza wins new CHMP nod

AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.

26th February 2018

Thumbnail image for Priority review for Shire’s HAE drug

Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).

23rd February 2018

Thumbnail image for Finalists soon to be revealed!

Finalists soon to be revealed!

Clinical researchers the world over have submitted essays for this year's competition and yesterday, the authors and finalists were identified at a special meeting of the executive steering group

23rd February 2018

Thumbnail image for NICE sticks with ‘no’ for earlier use of Halaven

NICE sticks with ‘no’ for earlier use of Halaven

Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.

22nd February 2018

Thumbnail image for Major study backs efficacy of antidepressants

Major study backs efficacy of antidepressants

A large-scale review of the most common antidepressants has found them all to be superior to placebo in treating major depression, potentially laying to rest questions over their effectiveness.

22nd February 2018

Previous  --   9 10 11 12 13 14 15 16 17 18   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download